Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Obesity panel impressed as Orexigen follows wise counsel and checks reality

This article was originally published in Scrip

Executive Summary

In a year that saw its two biotech rivals fail to achieve a positive recommendation from US FDA advisory panels for their obesity drugs, and one that saw pharmaceutical drugs for obesity withdrawn from the market, Orexigen Therapeutics rescued obesity from the stigma of being a graveyard indication by answering a question that the FDA wanted answering even though they did not explicitly demand it.

Topics

Related Companies

UsernamePublicRestriction

Register

SC011057

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel